Therapeutic drug monitoring of children and adolescents treated with fluoxetine

Pharmacopsychiatry

Volumn 45, Issue 2, 2012, Pages 72-76

  Koelch, M ^a   Pfalzer, A K ^a   Kliegl, K ^a   Rothenhofer S ^b   Ludolph, A G ^a   Fegert, J M ^a   Burger, R ^c   Mehler Wex, C ^a   Stingl, J ^a   Taurines, R ^c   Egberts, K ^c   Gerlach, M ^c  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

adolescents; antidepressants; children; pharmacokinetics; therapeutic drug monitoring

Indexed keywords

FLUOXETINE;

ADOLESCENT; ADULT; AGE; AGGRESSION; ARTICLE; BODY WEIGHT; CHILD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; GENDER; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NERVOUSNESS; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; SMOKING; SOMNOLENCE; TREATMENT OUTCOME; WEIGHT GAIN;

ADOLESCENT; AGE FACTORS; CHILD; COHORT STUDIES; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEASIBILITY STUDIES; FEMALE; FLUOXETINE; HUMANS; MALE; SEROTONIN UPTAKE INHIBITORS; SEX CHARACTERISTICS; SMOKING; YOUNG ADULT;

EID: 84858446980     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0031-1291294     Document Type: Article

References (17)

1. Goodyer I, Dubicka B, Wilkinson P et al. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. BMJ: 2007; 335 7611 142
2. March J, Silva S, Petrycki S et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for adolescents with depression study (TADS) randomized controlled trial. JAMA: 2004; 292 807 820 (Pubitemid 39079667)
3. Altamura A C, Moro A R, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet: 1994; 26 201 214 (Pubitemid 24081625)
4. Bergstrom R F, Lemberger L, Farid N A et al. Clinical pharmacology and pharmacokinetics of fluoxetine: a review. Br J Psychiatry Suppl: 1988; 3 47 50
5. Baumann P, Hiemke C, Ulrich S et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry: 2004; 37 243 265 (Pubitemid 39587052)
6. Wilens T E, Cohen L, Biederman J et al. Fluoxetine pharmacokinetics in pediatric patients. J Clin Psychopharmacol: 2002; 22 568 575 (Pubitemid 35416782)
7. Cherma M D, Ahlner J, Bengtsson F et al. Antidepressant drugs in children and adolescents, analytical and demographic data in a naturalistic, clinical study. J Clin Psychopharmacol: 2011; 31 98 102
8. Reis M, Aamo T, Spigset O et al. Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit: 2009; 31 42 56
9. Hammad T A, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry: 2006; 63 332 339 (Pubitemid 43345358)
10. Safer D J, Zito J M. Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. J Child Adolesc Psychopharmacol: 2006; M; 16 159 169
11. Mehler-Wex C, Kölch M, Kirchheiner J et al. Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy. Child Adolesc Psychiatry Ment Health: 2009; 3 14
12. Guy W. ECDEU assessment manual. Rockville, National Institute of Mental Health: 1976
13. Lingjaerde O, Ahlfors U G, Bech P et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl: 1987; 334 1 100 (Pubitemid 17115352)
14. Scordo M G, Spina E, Dahl M-L et al. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol: 2005; 97 296 301 (Pubitemid 41608122)
15. Miksys S, Tyndale R F. Nicotine induces brain CYP enzymes: relevance to Parkinson's disease. J Neural Transm Suppl: 2006; 70 177 180 (Pubitemid 44622197)
16. Aklillu E, Persson I, Bertilsson L et al. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther: 1996; 278 441 446 (Pubitemid 27167124)
17. Holtkamp K, Konrad K, Kaiser N et al. A retrospective study of SSRI treatment in adolescent anorexia nervosa: insufficient evidence for efficacy. J Psychiatr Res: 2005; 39 303 310 (Pubitemid 40255915)